3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
37
Carcinoma, Non-Small-Cell Lung
24
Squamous Cell Carcinoma of Head and Neck
18
Melanoma
17
Colorectal Neoplasms
16
Urinary Bladder Neoplasms
11
Breast Neoplasms
11
Liver Neoplasms
10
Biliary Tract Neoplasms
10
Small Cell Lung Carcinoma
9
Prostatic Neoplasms
9
Lung Neoplasms
9
Diabetes Mellitus, Insulin-Dependent, 12
9
Carcinoma, Renal Cell
9
Neoplasms
8
Cholangiocarcinoma
7
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Adenocarcinoma Of Esophagus
6
Stomach Neoplasms
5
Neoplasm Metastasis
5
Mesothelioma, Malignant
5
Fallopian Tube Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Mesothelioma
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Interventions
tremelimumab
1
pembrolizumab
1
enfortumab vedotin
1
durvalumab
1
atezolizumab
1
Watchful Waiting
1
Radiotherapy
1
Palliative Care
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Muscle-invasive Bladder Cancer
×
tremelimumab
×
Clear all
NCT03234153
2020-06-17
NITIMIB
Insel Gruppe AG, University Hospital Bern
Phase 2
Terminated
6 enrolled